Clinical trials: Growth Disorders
Lung Function
eCPAP Follow-up at School Age
The purpose of the study is to learn more about extended continuous positive airway pressure (eCPAP) in preterm infants that may be helpful for lung health.
- Trial name
- NCT07860931
- Testing
- Extended CPAP (eCPAP)
- Volunteers
- 95 people
- Sponsor
- Cynthia McEvoy
Iron Deficiency Anemia (IDA), Nutrition Disorders
Nutritional Educational Program On Therapy in Iron Deficiency Anemia
The goal of this clinical trial is to evaluate whether a Nutritional Educational Program for caregivers can improve their knowledge and performance in managing iron deficiency anemia (IDA) in children, compared to oral iron…
- Conditions
- Iron Deficiency Anemia (IDA), Nutrition Disorders, Growth Retardation
- Trial name
- NEPOT-IDA (NCT06642337)
- Testing
- Educational program
- Where
- Iraq
- Volunteers
- 180 people
- Sponsor
- Hawler Medical University
Colorectal Neoplasms
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
The purpose of this study was to assess the preliminary antitumor activity, safety and tolerability of tepotinib in combination with cetuximab in participants with RAS/BRAF wild-type left-sided Metastatic Colorectal Cancer (mCRC)…
- Trial name
- NCT04515394
- Testing
- Tepotinib, Cetuximab
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Growth Hormone Deficiency
Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency
The purpose of this study is to evaluate the efficacy and safety of recombinant human growth hormone on adult growth hormone deficiency
- Trial name
- NCT02693522
- Testing
- somatropin, Eutropin
- Where
- South Korea
- Volunteers
- 52 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Breast Cancer
Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan
This is a retrospective, multicenter, observational study in Japan by medical record review of advanced breast cancer (ABC) patients who have received palbociclib plus endocrine therapy (ET) as first line or second line setting.
- Trial name
- NCT05399329
- Testing
- Palbociclib, Endocrine therapy
- Where
- 20 sites in Japan
- Volunteers
- 693 people
- Sponsor
- Pfizer
Breast Cancer
A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), an enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of…
- Trial name
- NCT06115902
- Testing
- TQB2102 for injection
- Where
- 20 sites in China
- Volunteers
- 153 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Gastric Cancer
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
This study is to compare and evaluate the efficacy and safety of ONO-4538 in combination with ipilimumab and chemotherapy versus chemotherapy in chemotherapy-naïve participants with HER2-negative unresectable advanced or…
- Trial name
- NCT05144854
- Testing
- ONO-4538, Ipilimumab, Oxaliplatin
- Where
- 57 sites in Japan, South Korea and 1 more
- Volunteers
- 626 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Self Efficacy, Neoplasms (Cancer / Tumors)
Identifying and Mobilizing Personal Resources to Improve Well-Being in Cancer Participants Using the CAERES Protocol
Cancer patients often experience emotional distress, fatigue, and reduced quality of life that may not be fully addressed by medical treatment alone.
- Conditions
- Self Efficacy, Neoplasms (Cancer / Tumors), Cancer-related Fatigue, Post-Traumatic Growth, Psychological
- Trial name
- CAERES (NCT07582666)
- Testing
- CAERES (Cancer Auto-Evaluation of RESources) Psychosocial Intervention
- Where
- 3 sites in Switzerland
- Volunteers
- 32 people
- Sponsor
- UniDistance Suisse
Short Bowel Syndrome
rHGH and Intestinal Permeability in Intestinal Failure
Patients who are being asked to participate in this study have a short small bowel and will be prescribed to take the medication: Zorbtive® ("Zorbtive/Somatropin/(rHGH)").
- Trial name
- rHGH (NCT01380366)
- Testing
- Somatropin, Seven Day Food Diary, Blood Tests (standard of care)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Fractures in Children, Apophysitis
Total Genotype Score, Growth, Maturation and Loading Exposure as Risk Factors for Injury in Elite Male Youth Football
A total genotype risk score was generated based on the findings of previous research for non-contact injury, non-contact muscle injury, tendon injury, ligament injury, fracture injury and apophysitis injury.
- Conditions
- Fractures in Children, Apophysitis, Muscle Strain, Ligament Injury
- Trial name
- NCT05220969
- Testing
- Total Genotype Risk Score
- Where
- 2 sites in United Kingdom
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- St Mary's University College
Cancer
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
This is a two center, open label, non-randomized Phase II study of lenvatinib in adult subjects with recurrent or refractory advanced cancers with aberration(s) in FGF/FGFR signaling.
- Trial name
- NCT02846766
- Testing
- Lenvatinib
- Where
- 2 sites in United States
- Sponsor
- Teresa Helsten, MD
Stage IV Non-Small Cell Lung Cancer
Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer
The objective is to evaluate the toxicity profile, response rate, and time to progression of Cetuximab administered in combination with either Carboplatin + Gemcitabine in patients with advanced non-small cell lung cancer with…
- Trial name
- NCT01004731
- Testing
- Cetuximab in combination with Carboplatin/Gemcitabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Alabama at Birmingham
HER2-negative Breast Cancer, Stage II Breast Cancer
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Conditions
- HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00679029
- Testing
- doxorubicin hydrochloride, cyclophosphamide, bevacizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Nebraska
Twin; Pregnancy, Affecting Fetus or Newborn, Fetal Growth Retardation
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
Optimal diagnostic management and underlying pathophysiological mechanisms of selective fetal growth restriction (sFGR) in monochorionic diamniotic (MCDA) twin pregnancies have not been fully clarified.
- Conditions
- Twin; Pregnancy, Affecting Fetus or Newborn, Fetal Growth Retardation, Twin Monochorionic Diamniotic Placenta, Twin Diseases
- Trial name
- CONTRAST (NCT05952583)
- Testing
- Ultrasound
- Where
- 6 sites in United States, Belgium and 4 more
- Volunteers
- 274 people
- Sponsor
- Leiden University Medical Center
Malnutrition
District-based Mainstreaming Nutrition Project in Rural Pakistan
This study aims to provide evidence regarding the feasibility of integrating an enhanced maternal and child care health education package into the existing curricula of the National Program for Family Planning and Primary Health…
- Trial name
- NF Nutrition (NCT00816946)
- Testing
- Enhanced education
- Where
- Pakistan
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Fetal Growth Retardation, Fetal; Slow Growth
Third Trimester Screening of Fetal Growth Restriction
The aim of this trial is to assess the efficacy of two screening protocols for the detection of fetal growth disorders. In Italy at the moment the screening protocol should not be universal but only on clinical indications.
- Trial name
- RELAIS (NCT05787054)
- Testing
- Third trimester ultrasound
- Where
- Italy
- Volunteers
- 813 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Androgen Receptor Abnormal, Insulin-Like Growth Factor I Deficiency
AR, IGF-IR, IR and Peripheral Artery Disease
Peripheral artery Disease (PAD) is a major cardiovascular disease that can impair quality of life (QoL). It affects more often male patients and its pathophysiology is not completely known.
- Conditions
- Androgen Receptor Abnormal, Insulin-Like Growth Factor I Deficiency, Insulin Receptor, Defect in
- Trial name
- ANIMALPAD (NCT04710186)
- Testing
- arterial reconstructive open surgery
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Catanzaro
Anemia and Pregnancy, Metabolism and Foetal Growth
Foetal Exposure and Epidemiological Transition: Role of Anaemia in Early Life for Non-communicable Diseases Later
Study Hypotheses: 1. Anaemia, which is frequent before conception as well as during early pregnancy, affects metabolism and foetal growth trajectories, influencing the risk of NCDs in the offspring. 2.
- Conditions
- Anemia and Pregnancy, Metabolism and Foetal Growth, Epigenetics
- Trial name
- FOETALforNCD (NCT02191683)
- Where
- Tanzania
- Volunteers
- 1,748 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Metastatic Pancreatic Cancer
The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib
The purpose of this study is to investigate the influence of epidermal growth factor receptor mutations on the efficacy of erlotinib and gemcitabine in metastatic pancreatic cancer.
- Trial name
- NCT01608841
- Testing
- Erlotinib
- Where
- Taiwan
- Volunteers
- 88 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Cardiovascular Diseases, Heart Diseases
Fetal Growth Restriction & Maternal Cardiovascular Risk
To determine whether or not women with a history of having a baby with intrauterine growth retardation (IUGR) was more likely to have risk factors for cardiovascular disease versus women with a pregnancy not complicated by IUGR.
- Trial name
- NCT00241683
- Volunteers
- 704 people
- Sponsor
- The University of Texas Health Science Center, Houston